• Enovis Corporation recently reported fourth-quarter and full-year 2025 results, including sales of US$575.76 million for the quarter and US$2.25 billion for the year, alongside a goodwill impairment charge of US$501.31 million that contributed to a full-year net loss of US$1.18 billion.
• Alongside these results, Enovis issued 2026 revenue guidance of approximately US$2.31 billion to US$2.37 billion, signaling expectations for 4–6% organic growth even as substantial impairment charges continue to affect reported earnings.
• We will now examine how Enovis’ 2026 revenue guidance and large goodwill impairment charge may reshape the company’s investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.

Enovis Investment Narrative Recap

To own Enovis, you need to believe that its orthopedic portfolio and enabling technologies can eventually turn growing sales into sustainable profitability, despite today’s sizable losses. The latest results and 2026 revenue guidance suggest the top line remains on an upward path, while the goodwill impairment underlines how past acquisitions are still being digested. For now, the biggest near term catalyst remains consistent organic growth in orthopedics, and the largest risk is that integration and impairment issues keep weighing on earnings quality.

The 2026 revenue guidance of US$2.31 billion to US$2.37 billion, implying 4–6% organic growth, is the announcement that matters most here. It frames how management currently sees demand for Enovis’ orthopedic offerings after a year of heavy goodwill write downs. For investors watching catalysts, that guidance sits against a backdrop of ongoing integration work, capital commitments, and regulatory costs that all have the potential to influence how much of that revenue eventually turns into cash.

Yet even as guidance points to growth, the scale and recurrence of impairment charges is something investors should be aware of, because it raises questions about...

Enovis' narrative projects $2.6 billion revenue and $329.3 million earnings by 2028.

Uncover how Enovis' forecasts yield a $45.09 fair value, a 89% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenue near US$2.7 billion and earnings of about US$386 million by 2028, which paints a far more upbeat picture than consensus and highlights how differently you and other shareholders might weigh execution risks around innovation and integration once these latest results and impairments are fully reflected in the numbers.

Explore 2 other fair value estimates on Enovis - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Enovis research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Enovis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Enovis' overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.